The drug - a metoclopramide nasal spray - is intended to relieve symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus and recently completed a Phase IIb trial, also carried out by SynteractHCR.
Evoke’s CEO, Dave Gonyer, said: “As we prepare to commence this important initiative, we believe the selection of the same CRO and the planned inclusion of many of the same Phase IIb study sites will maximize the use of our knowledge base to expedite initiation and completion of Phase III.”
The Phase 3 enrollment target is 200 completed patients and enrollment is expected to begin in the first half of 2014.
Synteract and HCR merged earlier this year, creating a combined workforce of over 800 operating in 16 different countries.